| Medical and Health Sciences | Lifetime | 448 | DE 12 | 99.98 |
| Surgery | Lifetime | 219 | DE 8 | 99.81 |
| Epidemiology | Lifetime | 169 | DE 9 | 99.79 |
| Cardiology and Cardiovascular Medicine | Lifetime | 444 | DE 25 | 99.39 |
| Pulmonary and Respiratory Medicine | Lifetime | 686 | DE 33 | 98.98 |
| Endocrinology, Diabetes and Metabolism | Lifetime | 629 | DE 24 | 97.99 |
| Immunology | Lifetime | 707 | DE 49 | 97.78 |
| Nephrology | Lifetime | 550 | DE 19 | 93.79 |
| Radiation Physics | Lifetime | 886 | DE 71 | 83.85 |
| Surgery | 2021-2025 | 50 | DE 3 | 99.70 |
| Cardiology and Cardiovascular Medicine | 2021-2025 | 490 | DE 32 | 92.97 |
| Adipokines, Inflammation, and Metabolic Diseases | Lifetime | 11 | DE 1 | 99.92 |
| Lipoproteins and Cardiovascular Health | Lifetime | 12 | DE 1 | 99.89 |
| Atherosclerosis and Cardiovascular Diseases | Lifetime | 16 | DE 2 | 99.80 |
| Blood properties and coagulation | Lifetime | 12 | DE 2 | 99.64 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | Lifetime | 73 | DE 1 | 99.64 |
| Cardiovascular Disease and Adiposity | Lifetime | 109 | DE 4 | 99.35 |
| Lipid metabolism and disorders | Lifetime | 71 | DE 1 | 98.90 |
| Acute Myocardial Infarction Research | Lifetime | 232 | DE 14 | 99.24 |
| Inflammasome and immune disorders | Lifetime | 180 | DE 13 | 98.05 |
| Health Systems, Economic Evaluations, Quality of Life | Lifetime | 661 | DE 12 | 98.48 |
| Inflammatory Biomarkers in Disease Prognosis | Lifetime | 168 | DE 5 | 96.03 |
| Blood Pressure and Hypertension Studies | Lifetime | 608 | DE 17 | 98.28 |
| Biomarkers in Disease Mechanisms | Lifetime | 83 | DE 5 | 96.32 |
| Cancer, Lipids, and Metabolism | Lifetime | 968 | DE 40 | 96.69 |
| Climate Change and Health Impacts | Lifetime | 610 | DE 17 | 96.22 |
| GDF15 and Related Biomarkers | Lifetime | 94 | DE 15 | 93.71 |
| Chronic Kidney Disease and Diabetes | Lifetime | 546 | DE 30 | 97.15 |
| Protease and Inhibitor Mechanisms | Lifetime | 777 | DE 58 | 95.81 |
| Pharmaceutical Economics and Policy | Lifetime | 564 | DE 15 | 94.23 |
| Health Promotion and Cardiovascular Prevention | Lifetime | 427 | DE 33 | 92.15 |
| Macrophage Migration Inhibitory Factor | Lifetime | 411 | DE 37 | 89.10 |
| ICT Impact and Policies | Lifetime | 995 | DE 40 | 86.36 |
| Lipoproteins and Cardiovascular Health | 2021-2025 | 20 | DE 1 | 99.52 |
| Health Systems, Economic Evaluations, Quality of Life | 2021-2025 | 141 | DE 5 | 98.14 |
| Atherosclerosis and Cardiovascular Diseases | 2021-2025 | 60 | DE 5 | 96.18 |
| Pharmaceutical Economics and Policy | 2021-2025 | 73 | DE 5 | 94.69 |
| Adipokines, Inflammation, and Metabolic Diseases | 2021-2025 | 221 | DE 17 | 89.72 |
| Inflammasome and immune disorders | 2021-2025 | 354 | DE 10 | 90.07 |
| Diabetes, Cardiovascular Risks, and Lipoproteins | 2021-2025 | 801 | DE 21 | 85.78 |
| Takotsubo Cardiomyopathy and Associated Phenomena | 2021-2025 | 582 | DE 45 | 50.35 |
| Biomarkers in Disease Mechanisms | 2021-2025 | 593 | DE 6 | 50.66 |
| Apelin-related biomedical research | 2021-2025 | 768 | DE 35 | 31.70 |
